PE20211892A1 - Composicion liquida de clotrimazol envasada de dosis unica - Google Patents
Composicion liquida de clotrimazol envasada de dosis unicaInfo
- Publication number
- PE20211892A1 PE20211892A1 PE2021001191A PE2021001191A PE20211892A1 PE 20211892 A1 PE20211892 A1 PE 20211892A1 PE 2021001191 A PE2021001191 A PE 2021001191A PE 2021001191 A PE2021001191 A PE 2021001191A PE 20211892 A1 PE20211892 A1 PE 20211892A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- peg
- single dose
- polyethylene
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una composicion solucion liquida esteril farmaceutica o veterinaria, en donde dicha composicion comprende de 0,1% hasta 5% en peso (con respecto al volumen total de la composicion) de clotrimazol o una sal farmaceutica o veterinaria aceptable de este; un agente solubilizante seleccionado de polietilenglicol (PEG) tal como PEG 200, PEG 300, PEG 400, PEG 600 o una mezcla de los mismos, entre otros; y un contenido de agua igual o inferior a 4% en peso respecto al peso total de la composicion. Dicha composicion se encuentra en una unidad de envasado de dosis unica fabricado a partir de un polimero termoplastico seleccionado de polietileno (PE), polietileno de baja densidad (LDPE), polietileno de alta densidad (HDPE), polipropileno (PP) o una mezcla de los mismos, en donde dicha unidad de envasado de dosis unica es un envase soplado, llenado y sellado (blow-fill-seal, BFS) que tiene un volumen desde 0,05 mL hasta 8 mL. La composicion envasada de dosis unica de la presente invencion es esteril, homogenea y estable sin la presencia de conservantes que puedan causar efectos secundarios no deseados, permitiendo la administracion de una dosis mas exacta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382120 | 2019-02-19 | ||
| PCT/EP2020/054250 WO2020169611A1 (en) | 2019-02-19 | 2020-02-18 | Single-dose packaged clotrimazole liquid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211892A1 true PE20211892A1 (es) | 2021-09-22 |
Family
ID=65766941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001191A PE20211892A1 (es) | 2019-02-19 | 2020-02-18 | Composicion liquida de clotrimazol envasada de dosis unica |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20220133695A1 (es) |
| EP (1) | EP3927310B1 (es) |
| JP (1) | JP7514844B2 (es) |
| KR (1) | KR20210131313A (es) |
| AU (1) | AU2020225663B2 (es) |
| CA (1) | CA3127151A1 (es) |
| CL (1) | CL2021001882A1 (es) |
| CO (1) | CO2021010326A2 (es) |
| CR (1) | CR20210473A (es) |
| DO (1) | DOP2021000169A (es) |
| ES (1) | ES2980452T3 (es) |
| HR (1) | HRP20240866T1 (es) |
| IL (1) | IL284858A (es) |
| MA (1) | MA55007A (es) |
| MD (1) | MD3927310T2 (es) |
| MX (1) | MX2021008803A (es) |
| PE (1) | PE20211892A1 (es) |
| PL (1) | PL3927310T3 (es) |
| RS (1) | RS65657B1 (es) |
| SA (1) | SA521422538B1 (es) |
| SG (1) | SG11202107773RA (es) |
| TW (1) | TWI834808B (es) |
| WO (1) | WO2020169611A1 (es) |
| ZA (1) | ZA202105236B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069750B (zh) | 2016-04-25 | 2021-09-07 | 科斯卡家族有限公司 | 药物输送系统 |
| WO2024054865A2 (en) * | 2022-09-07 | 2024-03-14 | Combangio, Inc. | Preparation and purification methods for mesenchymal stem cell derived secretome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2563365A1 (en) | 2004-04-23 | 2005-11-03 | Mystic Pharmaceuticals, Inc. | Multiple unit dose drug delivery system |
| DE102005055385A1 (de) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
| EP2094264A1 (en) * | 2006-11-16 | 2009-09-02 | E-Therapeutics Limited | Clotrimazol for treating staphylococcal infections |
| GB0700380D0 (en) | 2007-01-09 | 2007-02-14 | Breath Ltd | Storage Of Ampoules |
| WO2012083138A2 (en) * | 2010-12-16 | 2012-06-21 | Board Of Regents, The University Of Texas System | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| US8933112B2 (en) * | 2012-06-15 | 2015-01-13 | Memphaceuticals, LLC | Topical liquid to ameliorate pain and promote healing of burn-injured skin |
| US9849126B2 (en) | 2013-01-03 | 2017-12-26 | Entrx LLC | Sterile otic formulations |
-
2020
- 2020-02-11 TW TW109104210A patent/TWI834808B/zh active
- 2020-02-18 ES ES20704341T patent/ES2980452T3/es active Active
- 2020-02-18 PL PL20704341.5T patent/PL3927310T3/pl unknown
- 2020-02-18 KR KR1020217022723A patent/KR20210131313A/ko unknown
- 2020-02-18 EP EP20704341.5A patent/EP3927310B1/en active Active
- 2020-02-18 JP JP2021541048A patent/JP7514844B2/ja active Active
- 2020-02-18 HR HRP20240866TT patent/HRP20240866T1/hr unknown
- 2020-02-18 RS RS20240686A patent/RS65657B1/sr unknown
- 2020-02-18 AU AU2020225663A patent/AU2020225663B2/en active Active
- 2020-02-18 US US17/310,260 patent/US20220133695A1/en active Pending
- 2020-02-18 MX MX2021008803A patent/MX2021008803A/es unknown
- 2020-02-18 CR CR20210473A patent/CR20210473A/es unknown
- 2020-02-18 PE PE2021001191A patent/PE20211892A1/es unknown
- 2020-02-18 CA CA3127151A patent/CA3127151A1/en active Pending
- 2020-02-18 MA MA055007A patent/MA55007A/fr unknown
- 2020-02-18 MD MDE20211243T patent/MD3927310T2/ro unknown
- 2020-02-18 SG SG11202107773RA patent/SG11202107773RA/en unknown
- 2020-02-18 WO PCT/EP2020/054250 patent/WO2020169611A1/en active Application Filing
-
2021
- 2021-07-14 SA SA521422538A patent/SA521422538B1/ar unknown
- 2021-07-14 IL IL284858A patent/IL284858A/en unknown
- 2021-07-15 CL CL2021001882A patent/CL2021001882A1/es unknown
- 2021-07-23 ZA ZA2021/05236A patent/ZA202105236B/en unknown
- 2021-08-05 CO CONC2021/0010326A patent/CO2021010326A2/es unknown
- 2021-08-13 DO DO2021000169A patent/DOP2021000169A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS65657B1 (sr) | 2024-07-31 |
| TW202045161A (zh) | 2020-12-16 |
| KR20210131313A (ko) | 2021-11-02 |
| SA521422538B1 (ar) | 2024-03-28 |
| MD3927310T2 (ro) | 2024-08-31 |
| TWI834808B (zh) | 2024-03-11 |
| JP2022520714A (ja) | 2022-04-01 |
| AU2020225663A1 (en) | 2021-08-12 |
| WO2020169611A1 (en) | 2020-08-27 |
| CA3127151A1 (en) | 2020-08-27 |
| CL2021001882A1 (es) | 2022-02-11 |
| CR20210473A (es) | 2021-10-08 |
| DOP2021000169A (es) | 2021-09-30 |
| JP7514844B2 (ja) | 2024-07-11 |
| US20220133695A1 (en) | 2022-05-05 |
| ZA202105236B (en) | 2023-10-25 |
| AU2020225663B2 (en) | 2024-03-14 |
| PL3927310T3 (pl) | 2024-08-05 |
| ES2980452T3 (es) | 2024-10-01 |
| HRP20240866T1 (hr) | 2024-10-11 |
| MX2021008803A (es) | 2021-11-12 |
| SG11202107773RA (en) | 2021-08-30 |
| CO2021010326A2 (es) | 2021-08-19 |
| CN113423382A (zh) | 2021-09-21 |
| IL284858A (en) | 2021-08-31 |
| EP3927310A1 (en) | 2021-12-29 |
| EP3927310B1 (en) | 2024-04-10 |
| EP3927310C0 (en) | 2024-04-10 |
| MA55007A (fr) | 2021-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211892A1 (es) | Composicion liquida de clotrimazol envasada de dosis unica | |
| JP5711868B2 (ja) | 安定なエダラボン含有水性製剤 | |
| JP2020203944A (ja) | 眼科用水性組成物 | |
| WO2018218013A3 (en) | STERILIZABLE PHARMACEUTICAL PACKAGING FOR OPHTHALMIC FORMULATIONS | |
| JP2022062078A5 (es) | ||
| JP6159567B2 (ja) | 既製のゲムシタビン注入溶液 | |
| CN102647971A (zh) | 用于包含美洛昔康的组合物的容器 | |
| CO2021002433A2 (es) | Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente | |
| JP7262528B2 (ja) | ジルチアゼムの非経口投薬形態 | |
| JP2018083805A (ja) | 水性眼科組成物 | |
| HRP20200039T1 (hr) | Formulacija fosfomicina za parenteralnu primjenu | |
| HRP20020636A2 (en) | Pharmaceutical composition comprising pemetrexed with monothioglycerol l-cystein or thioglycolic acid | |
| JP2016155864A (ja) | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 | |
| ES2321875T3 (es) | Preparacion oftalmica esteril,multifase, sin emulsionante aplicable en gotas. | |
| RU2761519C2 (ru) | Композиции на основе сложного холинового эфира липоевой кислоты и способы стабилизации с получением фармацевтически пригодных продуктов, представляющих собой лекарственное средство | |
| JP2016022092A (ja) | エダラボン含有プラスチック容器 | |
| JP2022191328A (ja) | 水性組成物 | |
| JP2023030691A (ja) | 眼科組成物 | |
| JP7541984B2 (ja) | エピネフリンの安定な水性注射溶液 | |
| JP2009143902A (ja) | エダラボンを含有する安定な水溶性製剤 | |
| JP2006025953A (ja) | ホリナート類水溶液充填プレフィルドシリンジ包装体 | |
| JP6817497B2 (ja) | ペメトレキセドの静脈内注入剤形 | |
| Benabbes et al. | 3PC-044 Paraffin oil-based emulsion: influence of gum arabic and the mixing rate on emulsion stability | |
| Beld et al. | 3PC-042 A science-and risk-based strategy to qualify sterilised prefilled syringes as primary packaging material in a hospital pharmacy | |
| Beld et al. | 3PC-043 New formulation of norepinephrine solution in prefilled cyclic olefin sterilised syringes |